Do your patients with RA report persistent symptoms despite improved inflammatory markers? Listen to Dr. Wright discuss the importance of patient-focused measures and read about SELECT-COMPARE’s patient-driven data.
Upadacitinib is a JAK inhibitor that has been studied in a large Phase 3 program in RA, which included 6 trials (5 registrational) and approximately 5000 patients. Here we provide an overview of JAK inhibition as well as a closer look at the long-term efficacy and safety data from the SELECT-COMPARE Phase 3 trial, which evaluated upadacitinib versus adalimumab or placebo in patients with inadequate response to MTX.
In this disease education video series from GSK, leading rheumatologists and nephrologists share their perspectives on lupus nephritis and reflect upon the gaps that remain in our understanding and management of the disease.
Your patient with rheumatoid arthritis has not responded to their biologic DMARD – now what? This article highlights the results from SELECT-CHOICE, which is the second head-to-head Phase 3 trial of the JAK inhibitor, upadacitinib, in RA. In this study, upadacitinib was evaluated for noninferiority and superiority assessments vs abatacept, in patients with moderate-to-severe RA who had prior inadequate response to biologic DMARD(s).
Patients with axial spondyloarthritis (axSpA) present with a wide range of symptoms. Given the disease’s heterogeneous presentation, what tools can be used to monitor patients with axSpA and their response to treatment? How can symptoms be tracked and analyzed over time? This article examines some commonly used axSpA disease measures, moving them from esoteric concepts to practical tools for understanding clinical trials and use in everyday practice.